{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:14:29Z","timestamp":1767824069537,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T00:00:00Z","timestamp":1292889600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1038\/sj.bjc.6606063","type":"journal-article","created":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T20:57:25Z","timestamp":1292965045000},"page":"272-280","source":"Crossref","is-referenced-by-count":31,"title":["Single agent and combination studies of pralatrexate and molecular correlates of sensitivity"],"prefix":"10.1038","volume":"104","author":[{"given":"M","family":"Serova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Bieche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M-P","family":"Sablin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G J","family":"Pronk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Vidaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Cvitkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,21]]},"reference":[{"key":"BF6606063_CR1","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1096\/fasebj.5.12.1916088","volume":"5","author":"DR Appling","year":"1991","unstructured":"Appling DR (1991) Compartmentation of folate-mediated one-carbon metabolism in eukaryotes. FASEB J 5: 2645\u20132651","journal-title":"FASEB J"},{"key":"BF6606063_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10555-007-9049-z","volume":"26","author":"YG Assaraf","year":"2007","unstructured":"Assaraf YG (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev 26: 153\u2013181","journal-title":"Cancer Metastasis Rev"},{"key":"BF6606063_CR3","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1158\/1078-0432.CCR-06-1754","volume":"13","author":"CG Azzoli","year":"2007","unstructured":"Azzoli CG, Krug LM, Gomez J, Miller VA, Kris MG, Ginsberg MS, Henry R, Jones J, Tyson L, Dunne M, Pizzo B, Farmer A, Venkatraman E, Steffen R, Sirotnak FM (2007) A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clin Cancer Res 13: 2692\u20132698","journal-title":"Clin Cancer Res"},{"key":"BF6606063_CR4","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1038\/sj.onc.1204917","volume":"20","author":"I Bi\u00e8che","year":"2001","unstructured":"Bi\u00e8che I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R (2001) Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 20: 8109\u20138115","journal-title":"Oncogene"},{"key":"BF6606063_CR5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1172\/JCI112088","volume":"76","author":"BA Chabner","year":"1985","unstructured":"Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76: 907\u2013912","journal-title":"J Clin Invest"},{"key":"BF6606063_CR6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0026-895X(25)10531-2","volume":"48","author":"G Chen","year":"1995","unstructured":"Chen G, Wright JE, Rosowsky A (1995) Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. Mol Pharmacol 48: 758\u2013765","journal-title":"Mol Pharmacol"},{"key":"BF6606063_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27\u201355","journal-title":"Adv Enzyme Regul"},{"key":"BF6606063_CR8","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1200\/JCO.1998.16.9.2943","volume":"16","author":"G Cocconi","year":"1998","unstructured":"Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM (1998) Open, randomized, multicenter trial of raltitrexed vs fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol 16: 2943\u20132952","journal-title":"J Clin Oncol"},{"key":"BF6606063_CR9","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1021\/jm00067a020","volume":"36","author":"JI DeGraw","year":"1993","unstructured":"DeGraw JI, Colwell WT, Piper JR, Sirotnak FM (1993) Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 36: 2228\u20132231","journal-title":"J Med Chem"},{"key":"BF6606063_CR10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJM194806032382301","volume":"238","author":"S Farber","year":"1948","unstructured":"Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA (1948) Temporary remission in acute leukaemia in children produced by folio acid antagonist 4-aminopteroylglutamic acid (aminopterin). New England J Med 238: 787\u2013793","journal-title":"New England J Med"},{"key":"BF6606063_CR11","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.bcp.2008.12.026","volume":"77","author":"AK Fotoohi","year":"2009","unstructured":"Fotoohi AK, Assaraf YG, Moshfegh A, Hashemi J, Jansen G, Peters GJ, Larsson C, Albertioni F (2009) Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol 77: 1410\u20131417","journal-title":"Biochem Pharmacol"},{"key":"BF6606063_CR12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar M, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn Jr PA (2004) Randomized phase III trial of pemetrexed vs docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589\u20131597","journal-title":"J Clin Oncol"},{"key":"BF6606063_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0022-1759(89)90397-9","volume":"119","author":"MB Hansen","year":"1989","unstructured":"Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth\/cell kill. J Immunol Methods 119: 203\u2013210","journal-title":"J Immunol Methods"},{"key":"BF6606063_CR14","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/cncr.11741","volume":"98","author":"I Ifergan","year":"2003","unstructured":"Ifergan I, Meller I, Issakov J, Assaraf YG (2003) Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer 98: 1958\u20131966","journal-title":"Cancer"},{"key":"BF6606063_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00280-009-0954-4","volume":"64","author":"E Izbicka","year":"2009","unstructured":"Izbicka E, Diaz A, Streeper R, Wick M, Campos D, Steffen R, Saunders M (2009) Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol 64: 993\u2013999","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6606063_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1368-7646(98)80042-3","volume":"1","author":"G Jansen","year":"1998","unstructured":"Jansen G, Pieters R (1998) The role of impaired transport in (pre)clinical resistance to methotrexate: insights on new antifolates. Drug Resist Updat 1: 211\u2013218","journal-title":"Drug Resist Updat"},{"key":"BF6606063_CR17","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1182\/blood-2009-03-210989","volume":"113","author":"AG Marneros","year":"2009","unstructured":"Marneros AG, Grossman ME, Silvers DN, Husain S, Nuovo GJ, MacGregor-Cortelli B, Neylon E, Patterson M, O\u2019Connor OA, Zain JM (2009) Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma\/leukemia causing skin erosions. Blood 113: 6338\u20136341","journal-title":"Blood"},{"key":"BF6606063_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0006-2952(01)00824-3","volume":"63","author":"R Mauritz","year":"2002","unstructured":"Mauritz R, Peters GJ, Priest DG, Assaraf YG, Drori S, Kathmann I, Noordhuis P, Bunni MA, Rosowsky A, Schornagel JH, Pinedo HM, Jansen G (2002) Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol 63: 105\u2013115","journal-title":"Biochem Pharmacol"},{"key":"BF6606063_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","volume":"139","author":"OA O\u2019Connor","year":"2007","unstructured":"O\u2019Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ, Macgregor-Cortelli B, Neylon E, Sarasohn D, Dumetrescu O, Mould DR, Fleischer M, Zelenetz AD, Sirotnak F, Horwitz S (2007) Pralatrexate, a novel class of antifolates with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139: 425\u2013428","journal-title":"Br J Haematol"},{"key":"BF6606063_CR20","first-page":"6012","volume":"9","author":"E Odin","year":"2003","unstructured":"Odin E, Wettergren Y, Nilsson S, Will\u00e9n R, Carlsson G, Spears CP, Larsson L, Gustavsson B (2003) Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 9: 6012\u20136019","journal-title":"Clin Cancer Res"},{"key":"BF6606063_CR21","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1124\/mol.104.004135","volume":"66","author":"L Rothem","year":"2004","unstructured":"Rothem L, Stark M, Assaraf YG (2004) Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene. Mol Pharmacol 66: 1536\u20131543","journal-title":"Mol Pharmacol"},{"key":"BF6606063_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s002800050823","volume":"42","author":"FM Sirotnak","year":"1998","unstructured":"Sirotnak FM, DeGraw JI, Colwell WT, Piper JR (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42: 313\u2013318","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6606063_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/1078-0432.CCR-05-0331","volume":"12","author":"LE Toner","year":"2006","unstructured":"Toner LE, Vrhovac R, Smith EA, Gardner J, Heaney M, Gonen M, Teruya-Feldstein J, Sirotnak F, O\u2019Connor OA (2006) The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 12: 924\u2013932","journal-title":"Clin Cancer Res"},{"key":"BF6606063_CR24","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin vs cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2630\u20132636","journal-title":"J Clin Oncol"},{"key":"BF6606063_CR25","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/1042819031000077124","volume":"44","author":"ES Wang","year":"2003","unstructured":"Wang ES, O\u2019Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA (2003) Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 44: 1027\u20131035","journal-title":"Leuk Lymphoma"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6606063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6606063","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6606063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:35:00Z","timestamp":1740789300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6606063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,21]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["BF6606063"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6606063","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,21]]}}}